Lexar Laboratories & Analysis LLC

Lexar Laboratories & Analysis LLC was paid $11.58M by Medicaid between Jan 2018 and Mar 2024, across 84 billing codes. Its largest line is G0481, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed — 32% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Kentucky

Rank by total paid#11 of 73

Median peer was paid$95K

This provider vs. median122×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	77,537	$1.58M
2019	136,124	$2.25M
2020	70,418	$1.79M
2021	47,016	$1.74M
2022	36,055	$1.76M
2023	58,460	$2.08M
2024incomplete	11,085	$378K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	32%	60,944	38,086	$3.75M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	15%	22,972	13,501	$1.78M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	15%	68,096	42,218	$1.71M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	12%	26,860	18,350	$1.39M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	8.4%	10,859	6,351	$977K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	1.8%	5,293	4,618	$213K
87529		<1%	3,953	3,325	$112K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	3,382	3,115	$101K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	1,832	1,519	$89K
80369		<1%	11,929	7,151	$87K
80368		<1%	11,131	6,528	$67K
80365		<1%	10,764	6,798	$65K

72 more codes

87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	3,357	$57K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	3,331	$56K
80348		<1%	11,362	$54K
80361		<1%	6,749	$54K
87563		<1%	2,959	$51K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	2,955	$51K
80362		<1%	7,960	$50K
80346		<1%	6,713	$49K
80355		<1%	10,715	$47K
80372		<1%	8,021	$46K
80366		<1%	10,032	$45K
80349		<1%	7,132	$44K
87511		<1%	2,810	$44K
80363		<1%	3,500	$38K
80324		<1%	6,018	$37K
80356		<1%	6,319	$33K
80353		<1%	5,812	$33K
80358		<1%	5,641	$33K
80354		<1%	5,378	$32K
80321		<1%	4,373	$31K
80373		<1%	5,568	$31K
87481		<1%	2,941	$30K
80359		<1%	5,555	$30K
83992		<1%	5,593	$28K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	1,945	$25K
80323		<1%	7,375	$21K
80360		<1%	8,248	$21K
80371		<1%	6,439	$16K
87070		<1%	3,238	$14K
80325		<1%	4,198	$12K
80336		<1%	779	$12K
87631		<1%	212	$12K
80338		<1%	2,529	$12K
80345		<1%	3,937	$10K
80364		<1%	3,015	$10K
80335		<1%	2,525	$7K
87086	Culture, bacterial; quantitative colony count, urine	<1%	1,633	$7K
87186		<1%	1,034	$5K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	276	$5K
80332		<1%	1,010	$5K
87077		<1%	1,034	$5K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	178	$5K
80337		<1%	388	$4K
80074		<1%	237	$3K
87640		<1%	202	$3K
87634		<1%	247	$3K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	214	$3K
81025		<1%	196	$3K
84443	Thyroid stimulating hormone (TSH)	<1%	187	$2K
80053	Comprehensive metabolic panel	<1%	355	$2K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	320	$1K
87501		<1%	88	$1K
87486		<1%	76	$1K
87532		<1%	76	$1K
87541		<1%	76	$1K
87581		<1%	76	$1K
80061	Lipid panel	<1%	169	$1K
87503		<1%	147	$1K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	52	$935.70
80333		<1%	1,063	$837.30
87498		<1%	90	$663.13
87653		<1%	28	$536.85
83036	Hemoglobin; glycosylated (A1C)	<1%	67	$394.91
36415	Collection of venous blood by venipuncture	<1%	414	$342.64
80342		<1%	809	$320.41
84439		<1%	42	$218.22
84436		<1%	54	$128.15
82746		<1%	16	$116.73
83540		<1%	14	$54.60
83986		0%	857	$0.00
84311		0%	864	$0.00
82570		0%	857	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPELFREY, JENNIFER (OWNER)